Heidelberg Pharma AG receives shareholder loan based on existing financing commitment
Heidelberg Pharma AG / Keyword (s): Financing
Heidelberg Pharma AG receives shareholder loan based on existing financing commitment
21-Dec-2020 / 11:47 CET / CEST
Disclosure of inside information acc. in Article 17 MAR of Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this advertisement.
Ad hoc announcement – Inside information within the meaning of article 17 MAR
Heidelberg Pharma AG receives shareholder loan based on existing financing commitment
Ladenburg, Germany, December 21, 2020 – Heidelberg Pharma AG (FSE: HPHA) today announced that it has signed a subordinated loan agreement totaling EUR 15 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany. The loan amount corresponds to the financing commitment of July 21, 2020, which will secure the company’s cash flow until mid-2021.
The loan has no expiration date, is unsecured and has an interest rate of 6% per annum. Heidelberg Pharma AG can access the loan when needed.
Information and explanation from the issuer to this news:
About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop amanitin toxin in cancer therapies using its proprietary antibody-targeted amanitin conjugate (ATAC) technology and to advance the toxin’s biological mode of action. as a new therapeutic principle. This proprietary technology platform is used to develop the Company’s proprietary therapeutic ATACs as well as in collaborations with third parties to create a variety of ATAC candidates. The leading HDP-101 owner candidate is a BCMA ATAC for multiple myeloma.
The Company has entered into partnerships to continue the development and commercialization of its upamostat clinical assets (formerly MESUPRON(D)) and TLX250-CDx (formerly REDECTANE(D)). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.
| Contact Heidelberg Pharma SA Sylvie Wimmer Phone. : +49 89 41 31 38-29 Email: investors[at]hdpharma.com Gregor-Mendel-Str. 22, 68526 Ladenbourg |
IR / RP assistance MC Services SA Katja Arnold (CIRO) Managing Director and Partner Phone. : +49 89 210 228-40 Email: katja.arnold[at]mc-services.eu |
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terms such as “estimates”, “believes”, “expects”, “could”, “will”, “should” “Future”, “potential” or similar expressions or by a general discussion of the strategy, plans or intentions of the Company. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance or achievements, or results of the industry, to be significantly different from the expressed future results, performances or achievements. or implied by these forward-looking statements. In view of these uncertainties, potential investors and partners are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update these forward-looking statements to reflect future events or developments.
21-Dec-2020 CET / CEST DGAP’s distribution services include regulatory announcements, financial / corporate news and press releases.
Archives on www.dgap.de